Longview Home Page Marshal Home Page Linden Home Page
Health News Health Library Health Topics Healthy Living
Today's Headlines    Health Alerts    Health News Feature   
Future of Medicine    Health Observances    Product Recalls
Illnesses & Conditions    Drug Guide    FDA Drug Approvals    Medical Tests   
Self-Help Resources    Complementary Medicine    Medline Search
Allergies    Asthma    Back Pain    Cancer    Caregiver    Depression    Diabetes    Digestive Disorders
Heart Disease    Kidney Disease    Men's Health    Parenting    Pregnancy    Senior's Health
Stress    Stroke    Women's Health
Fitness    Nutrition    Mind & Body    Family & Home
 






SEARCH



Today's Headlines

Health News
Daily articles from HealthDay News: breaking news on health issues, drug approvals and recent discoveries.

New Therapy Kills Human Leukemia Cells in Mice


Technique expands natural killer cells in cord blood more than 30-fold

FRIDAY, May 16 (HealthDay News) A treatment that uses natural killer (NK) immune system cells from umbilical cord blood effectively destroys human leukemia cells in mice, researchers say.

The NK cells reduced by 60 percent to 85 percent human acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML) cells in test mice with aggressive human leukemias, according to the study.

The findings are to be presented at the May 16 American Society of Pediatric Hematology/Oncology annual conference, in Cincinnati.

Previous efforts like this one, which require the number of NK cells from a single cord blood to be expanded, resulted in ineffective NK cells. The new technique manages to increase NK cells in cord blood more than 30-fold while allowing the cells to retain their ability to target and kill acute leukemia cells.

"Cord blood is a promising source of natural killer cells, because the NK cells have enhanced sensitivity to stimulation, decreased potential to cause graft-versus-host disease and are available from cord banks throughout the country and world," investigator Dr. Patrick Zweidler-McKay, assistant professor of pediatrics from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center, said in a prepared statement.

Graft-versus-host disease is a common side effect of patients receiving stem cell transplants. It is fatal if not controlled.

The new process allows the NK cells to be transplanted to leukemia patients without the need for prior chemotherapy. Zweidler-McKay said that adults who have already had a transplant, or any age leukemia patient who is not eligible for other stem cell transplants due to blood counts or illness, may be available to use his new transplant method.

"These NK cells demonstrate significant cytotoxic activity against human AML and ALL cell lines and patient leukemia blasts. Most importantly, mouse models of human AML and ALL were sensitive to NK cell infusions," Zweidler-McKay said.

More information

The American Cancer Society has more about leukemia.

SOURCE: University of Texas M. D. Anderson Cancer Center, news release, May 16, 2008
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Health News Provided By:
HealthDay


 

 
Good Shepherd Health

Data and information on this site
has been compiled for public use.
GSMC will not be held liable for
errors or inaccuracies.
Privacy & Conditions of Use Policy.
Questions/Comments? Contact
webmaster.
© 1999-2002 Good Shepherd Health System
Recommended Browsers:
Microsoft Internet Explorer
Version 4.0 or above,
Netscape Navigator 4.0 or above,
Or Any HTML 4.0 browser.

.